Suppr超能文献

干扰素调节因子:人类狼疮的关键介质。

Interferon regulatory factors: critical mediators of human lupus.

作者信息

Jensen Mark A, Niewold Timothy B

机构信息

Division of Rheumatology, Department of Immunology, Mayo Clinic, Rochester, Minn.

Division of Rheumatology, Department of Immunology, Mayo Clinic, Rochester, Minn.

出版信息

Transl Res. 2015 Feb;165(2):283-95. doi: 10.1016/j.trsl.2014.10.002. Epub 2014 Oct 13.

Abstract

The pathogenesis of systemic lupus erythematosus (SLE) is multifactorial, and the interferon regulatory factors (IRFs) play an important role. Autoantibodies formed in SLE target nuclear antigens, and immune complexes formed by these antibodies contain nucleic acid. These immune complexes can activate antiviral pattern recognition receptors (PRRs), resulting in the downstream activation of IRFs, which can induce type I interferon (IFN-I) and other inflammatory mediators. Genetic variations in IRFs have been associated with susceptibility to SLE, and current evidence supports the idea that these polymorphisms are gain of function in humans. Recent studies suggest that these genetic variations contribute to the break in humoral tolerance that allows for nucleic acid binding autoantibodies, and that the same polymorphisms also augment IFN-I production in the presence of these autoantibody immune complexes, forming a feed-forward loop. In this review, we will outline major features of the PRR/IRF systems and describe the role of the IRFs in human SLE pathogenesis.

摘要

系统性红斑狼疮(SLE)的发病机制是多因素的,干扰素调节因子(IRF)发挥着重要作用。SLE中形成的自身抗体靶向核抗原,这些抗体形成的免疫复合物含有核酸。这些免疫复合物可激活抗病毒模式识别受体(PRR),导致IRF的下游激活,进而诱导I型干扰素(IFN-I)和其他炎症介质。IRF的基因变异与SLE易感性相关,目前的证据支持这些多态性在人类中具有功能获得性的观点。最近的研究表明,这些基因变异导致体液耐受性的破坏,从而产生核酸结合自身抗体,并且相同的多态性在这些自身抗体免疫复合物存在的情况下也会增加IFN-I的产生,形成一个前馈回路。在这篇综述中,我们将概述PRR/IRF系统的主要特征,并描述IRF在人类SLE发病机制中的作用。

相似文献

1
Interferon regulatory factors: critical mediators of human lupus.
Transl Res. 2015 Feb;165(2):283-95. doi: 10.1016/j.trsl.2014.10.002. Epub 2014 Oct 13.
2
Interferon regulatory factors in human lupus pathogenesis.
Transl Res. 2011 Jun;157(6):326-31. doi: 10.1016/j.trsl.2011.01.006. Epub 2011 Feb 8.
3
A compass that points to lupus: genetic studies on type I interferon pathway.
Genes Immun. 2007 Sep;8(6):445-55. doi: 10.1038/sj.gene.6364409. Epub 2007 Jun 21.
4
Interferon regulatory factor 5 in the pathogenesis of systemic lupus erythematosus.
Clin Dev Immunol. 2012;2012:780436. doi: 10.1155/2012/780436. Epub 2012 Nov 1.
6
[Interleukin-2 signaling pathway regulating molecules in systemic lupus erythematosus].
Beijing Da Xue Xue Bao Yi Xue Ban. 2016 Dec 18;48(6):1100-1104.
7
Interferon regulatory factor 5 is critical for the development of lupus in MRL/lpr mice.
Arthritis Rheum. 2011 Mar;63(3):738-48. doi: 10.1002/art.30183.
8
New insights into the immunopathogenesis of systemic lupus erythematosus.
Nat Rev Rheumatol. 2016 Nov 22;12(12):716-730. doi: 10.1038/nrrheum.2016.186.
9
Interferon regulatory factors: beyond the antiviral response and their link to the development of autoimmune pathology.
Autoimmun Rev. 2011 Dec;11(2):98-103. doi: 10.1016/j.autrev.2011.08.006. Epub 2011 Aug 18.
10
Linking interferon regulatory factors to the pathogenesis of human lupus.
Transl Res. 2011 Jun;157(6):323-5. doi: 10.1016/j.trsl.2011.02.011. Epub 2011 Mar 25.

引用本文的文献

2
The multiple roles of interferon regulatory factor family in health and disease.
Signal Transduct Target Ther. 2024 Oct 9;9(1):282. doi: 10.1038/s41392-024-01980-4.
3
Type I Interferons in Systemic Autoimmune Rheumatic Diseases: Pathogenesis, Clinical Features and Treatment Options.
Mediterr J Rheumatol. 2024 Jun 30;35(Suppl 2):365-380. doi: 10.31138/mjr.270324.tis. eCollection 2024 Jun.
4
The Role of Genetic Risk Factors in Pathogenesis of Childhood-Onset Systemic Lupus Erythematosus.
Curr Issues Mol Biol. 2023 Jul 17;45(7):5981-6002. doi: 10.3390/cimb45070378.
5
Type I Interferons in Autoimmunity.
J Invest Dermatol. 2022 Mar;142(3 Pt B):793-803. doi: 10.1016/j.jid.2021.11.031. Epub 2022 Jan 10.
8
Emerging roles of circular RNAs in systemic lupus erythematosus.
Mol Ther Nucleic Acids. 2021 Mar 1;24:212-222. doi: 10.1016/j.omtn.2021.02.028. eCollection 2021 Jun 4.
9
Autosomal Recessive ISG15 Deficiency Underlies Type I Interferonopathy with Systemic Lupus Erythematosus and Inflammatory Myositis.
J Clin Immunol. 2021 Aug;41(6):1361-1364. doi: 10.1007/s10875-021-01019-1. Epub 2021 Mar 19.
10
Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies.
Trends Mol Med. 2021 Feb;27(2):152-171. doi: 10.1016/j.molmed.2020.09.009. Epub 2020 Oct 9.

本文引用的文献

1
TRIpartite motif 21 (TRIM21) differentially regulates the stability of interferon regulatory factor 5 (IRF5) isoforms.
PLoS One. 2014 Aug 1;9(8):e103609. doi: 10.1371/journal.pone.0103609. eCollection 2014.
3
IRF5-mediated signaling and implications for SLE.
Clin Immunol. 2014 Aug;153(2):343-52. doi: 10.1016/j.clim.2014.06.001. Epub 2014 Jun 10.
4
Interferon regulatory factors: at the crossroads of immunity, metabolism, and disease.
Biochim Biophys Acta. 2015 Feb;1852(2):365-78. doi: 10.1016/j.bbadis.2014.04.030. Epub 2014 May 5.
5
Autoimmune disorders associated with gain of function of the intracellular sensor MDA5.
Immunity. 2014 Feb 20;40(2):199-212. doi: 10.1016/j.immuni.2013.12.014. Epub 2014 Feb 13.
6
Apoptotic cell clearance: basic biology and therapeutic potential.
Nat Rev Immunol. 2014 Mar;14(3):166-80. doi: 10.1038/nri3607. Epub 2014 Jan 31.
7
Genetics of the type I interferon pathway in systemic lupus erythematosus.
Int J Clin Rheumtol. 2013 Dec 1;8(6). doi: 10.2217/ijr.13.58.
8
Regulation of type I interferon responses.
Nat Rev Immunol. 2014 Jan;14(1):36-49. doi: 10.1038/nri3581.
9
Familial aggregation of high tumor necrosis factor alpha levels in systemic lupus erythematosus.
Clin Dev Immunol. 2013;2013:267430. doi: 10.1155/2013/267430. Epub 2013 Sep 25.
10
Nucleic Acid sensors and type I interferon production in systemic lupus erythematosus.
Front Immunol. 2013 Oct 7;4:319. doi: 10.3389/fimmu.2013.00319.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验